EU Strengthens Medicine Supply: A Leap Towards Self-Reliance
The European Union has reached a provisional deal to bolster its medicine supply by enhancing domestic production and reducing dependence on imports, targeting 270 critical medicines. This initiative, part of the Critical Medicines Act, aims to counter supply-chain vulnerabilities and is a response to disruptions in the pharmaceutical sector.
In a significant move, European Union lawmakers have struck a provisional deal to enhance the bloc's supply of essential medicines by ramping up domestic production and decreasing reliance on external imports.
This initiative arises as the region grapples with ensuring access to new drugs, challenged by U.S. pricing policies disrupting the pharmaceutical sector under former President Donald Trump. The agreement is a crucial development in the Critical Medicines Act, proposed by the European Commission, addressing supply-chain frailties for about 270 vital medications.
Emer Cooke of the European Medicines Agency emphasized the urgency of stabilizing medicine supply. The EU plans to boost manufacturing capacity, lessen dependency on China and India, and promote European production in public procurement, despite concerns about potential trade tensions with the U.S.
(With inputs from agencies.)
Google News